Until recently, only about 60 percent of the cystic fibrosis population was eligible for CFTR modulator therapy. Now, with the approval of Trikafta, a triple-combination CFTR modulator therapy, more than 90 percent of people with CF could eventually have a highly effective therapy for the underlying cause of their disease. Alex Gifford, MD, an associate professor of medicine and the director of the adult CF program at Dartmouth-Hitchcock, discusses clinical trials that study the effects of CFTR